Immuneering reports positive early Phase 1 data for IMM-1-104; accelerates RP2D timeline to early 2024

Immuneering Corp

IMM-1-104 shows >90% pERK inhibition at 160mg QD; PK Cmax >2,000 ng/mL; half-life ~2 hours.
No dose-limiting toxicities or SAEs; only Grade 1 drug-related AEs; well tolerated across four patients.
RP2D announcement accelerated to early 2024 from prior guidance of mid-2024.
Preliminary cash $91.5M at March 31, 2023; expected funding into Q4 2024.
Data from patients with pancreatic and colorectal cancer with KRAS G12D, G12V, NRAS Q61L, Q61K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.